Repatha launch date?

See the DrugPatentWatch profile for Repatha

When did Repatha (evolocumab) launch?

Repatha (evolocumab) was launched in the U.S. in 2015, after the FDA approved it for certain patients with hyperlipidemia and cardiovascular risk conditions.

What approval date does the launch line up with?

The U.S. FDA approval that enabled the product’s commercial launch occurred on August 27, 2015 (the date most launch timelines reference).

Was it launched in other countries around the same time?

Launch timing varied by country, because availability depends on each regulator’s approval and local pricing/coverage decisions. In most markets, rollouts started soon after the initial approvals in 2015.

Why are there multiple “launch” dates people cite?

“Launch” can refer to different milestones, such as:
- first regulatory approval (e.g., FDA approval in 2015),
- first shipment/commercial availability in a specific country,
- label expansion approvals later on.

Those events can create different dates in news articles, formularies, and analyst reports.

Source

• DrugPatentWatch.com: https://www.drugpatentwatch.com/